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Interventions for mesenteric vasculitis
Yevgeniy Rits, MD,a Gustavo S. Oderich, MD,a Thomas C. Bower, MD,a Dylan V. Miller, MD,b
Leslie Cooper, MD,c Joseph J. Ricotta II, MD,a Manju Kalra, MBBS,a and Peter Gloviczki, MD,a
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Objective: This study reviewed the outcomes of open and endovascular revascularization for mesenteric vasculitis (MV).
Methods: We reviewed the clinical data of all patients who underwent revascularization for occlusive MV from 1984 to
2008. Patients treated for aneurysms or mucosal bleeding without ischemic symptoms were excluded. End points were
early mortality and morbidity, survival, freedom frommesenteric symptoms, and patency. Outcomes of open reconstruc-
tions were compared with the results of 163 patients who underwent open operations for atherosclerotic disease.
Results: There were 15 patients (13 females, 2 males) with a mean age of 38 years (range, 15-66 years). Etiologies were
Takayasu’s arteritis in 7, polyarteritis nodosa in 4, indeterminate in 3, and giant cell arteritis in 1. The celiac axis was
affected in 13, superior mesenteric artery (SMA) in 13, renal arteries in 8, and the aorta in 4. Seven patients had active
disease, and eight were in remission. Nine (60%) presented with symptomatic chronic (n 8) and acute (n 1)mesenteric
ischemia. Six patients with asymptomatic disease underwent mesenteric revascularization during other aortic-based
operations. Fourteen patients (93%) had 10 mesenteric bypasses (8 aortic based; 2 iliac), three had aortoplasties, of which
two had mesenteric patch angioplasties, and one underwent arcuate ligament release with patch angioplasty. One patient
(7%) underwent percutaneous transluminal angioplasty of SMA stenosis. There were no early deaths. Early complications
occurred in three patients (20%) after open reconstruction, including gastrointestinal hemorrhage, ileus with re-
exploration, and superior mesenteric vein thrombosis. Median follow-up was 22 months. One graft thrombosis in a
patient with active disease was treated with redo bypass 74 months after aorta-celiac-SMA bypass. All patients were alive
at 10 years, with similar expected survival compared with the general population (P .69). Compared with patients with
atherosclerotic disease, open reconstructions for MV had similar freedom from mesenteric symptoms (83% vs 75%, P 
.80) and similar primary graft patency (83% vs 84%, P  .9).
Conclusion:Mesenteric vasculitis is a raremanifestation of Takayasu arteritis, polyarteritis nodosa, indeterminate, or giant
cell arteritis. Open revascularization is durable and effective when needed. (J Vasc Surg 2010;51:392-400.)Primary vasculitis is a rare disease characterized by
inflammation of the vessel wall.1 Chronic inflammation can
weaken the media and thin the arterial wall causing an
aneurysm, or it can cause arterial wall thickening leading to
stenoses and occlusions.2 The spectrum of vasculitis is
broad and may affect small-, medium-, or large-sized ves-
sels in different territories. Patients are often asymptomatic,
and mesenteric arteritis is found incidentally as part of an
evaluation for other systemic, renal, and cerebrovascular
symptoms.3
Most patients with chronic mesenteric ischemia have
ostial atherosclerotic lesions affecting at least two of the
three mesenteric arteries. Mesenteric vasculitis accounts for
5% of all cases of mesenteric ischemia, but the diagnosis
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392should be entertained in young patients without other
stigmata (eg, calcifications, atherosclerotic debris) of ath-
erosclerotic disease. Medical therapy is the first-line treat-
ment for vasculitis, but there is no consensus on the indi-
cations, timing, and outcomes of revascularization.
The purpose of this study was to review the clinical
presentation, indications, and results of open and endovas-
cular revascularization for occlusive mesenteric vasculitis.
In addition, the late outcomes of open revascularizations
performed formesenteric vasculitis were compared with the
results of open mesenteric reconstructions performed for
chronic atherosclerotic mesenteric ischemia.
METHODS
In this study, which was approved by the Mayo Foun-
dation Institutional Review Board, we used the Mayo
Clinic database and vascular surgery registry to identify all
consecutive patients diagnosed with vasculitis who under-
went mesenteric revascularization between January 1,
1984, and June 31, 2008. Patients who underwent revas-
cularization for mesenteric arterial stenoses or occlusions
caused by vasculitis were included in the study. Patients had
symptoms of mesenteric ischemia or were asymptomatic
but had mesenteric revascularization as part of other aortic-
based procedures performed for renovascular hypertension
or midaortic syndrome. All patients treated for asymptom-
atic lesions had vasculitis involving the paravisceral aorta,
mesenteric, and renal arteries. We excluded patients treated
for aneurysms, mucosal lesions, and those with gastrointes-
JOURNAL OF VASCULAR SURGERY
Volume 51, Number 2 Rits et al 393tinal bleeding without evidence of mesenteric ischemia or
mesenteric occlusive lesions.
The diagnosis of vasculitis was established by the clini-
cal or pathologic criteria recommended by the American
Rheumatology Association and Chapel Hill Consensus
Conference in 1994.4 Vasculitides were distinguished ac-
cording to the size of the vessel involved and then subclas-
sified according to the particular features of the specific
vasculitis; for example, Takayasu vasculitis affects large ves-
sels in patients aged 50 years. Specific features may in-
clude site involvement, patient age, type of inflammation,
pathologic features of the inflammation or specific deposits,
and markers that are available on staining or serology.
In addition, all cases were reviewed individually to
establish the diagnosis of occlusive mesenteric vasculitis,
defined by the presence of one or more high-grade (70%)
mesenteric artery stenoses or occlusions, typically long,
smooth tapered lesions with arterial wall thickening in the
absence of stigmata of atherosclerosis (calcification or ath-
erosclerotic debris), and pathologic or operative inflamma-
tory changes consistent with vasculitis.
Active disease was defined by two or more of the
following: pathologic, operative, laboratory, or clinical cri-
teria. These included systemic symptoms such as fevers
(38°C), myalgias, arthralgias; active inflammation on a
pathologic specimen taken from the diseased artery; ele-
vated erythrocyte sedimentation rate (normal range, 0-29
mm/h) or C-reactive protein (normal CRP 0.8 mg/dl);
or acute inflammation of the artery and surrounding soft
tissue at the time of the operation.
Medical management was the initial therapy except if
acute symptoms mandated operative intervention. Daily
prednisone was given at a dose of 40 to 60 mg for 4 to 6
weeks and tapered by 10% per week thereafter according to
clinical response. Other medications, such as cyclophosph-
amide or methotrexate, were added in such patients who
clinically did not respond to prednisone. Interventions
were reserved for patients with persistent symptoms when
medical therapy failed.
Demographics, cardiovascular risk factors, clinical pre-
sentation, operative data, and details of complications were
collected from patient records. Pathology specimens were
reviewed whenever possible. End points were early mortal-
ity and morbidity, patient survival, freedom from mesen-
teric symptoms, and vessel or graft patency. Perioperative
was defined as occurring in the hospital or 30 days after
the operation. Late follow-up data were obtained from
medical records, office visits, correspondence with referring
physicians, and telephone interviews.
Late outcome data for survival, freedom from mesen-
teric symptoms, and patency in patients who underwent
open revascularization for mesenteric vasculitis were com-
pared with the results of a cohort of 163 patients who had
had similar operations for chronic atherosclerotic mesen-
teric ischemia since 1990. Late survival of vasculitis patients
was also compared with age- and gender-matched controls
from the State of Minnesota. Patient survival, freedom
from mesenteric symptoms, and graft patency were ana-lyzed using the Kaplan-Meier method. Data were pre-
sented as median values or mean  standard deviation, as
appropriate. A value of P  .05 was significant.
RESULTS
Patient population. Of 7514 patients evaluated for
vasculitis during the 24 years of the study, 120 had symp-
toms of mesenteric ischemia. During the same time, 323
patients required open or endovascular mesenteric revascu-
larization for mesenteric ischemia and only 15 (4%) had
open or endovascular treatment for occlusive mesenteric
vasculitis. There were 13 female and 2 male patients with
mean age of 38  17 years.
Clinical presentation and diagnosis. Arteritis was
categorized as Takayasu arteritis in 7 patients, polyarteritis
nodosa in 4, indeterminate arteritis in 3, and giant cell
arteritis in 1. Nine patients (60%) presented with chronic
(n 8) or acute (n 1) symptoms of mesenteric ischemia.
Seven of these 9 patients (80%) had abdominal pain, which
was postprandial in four. Nausea and vomiting or weight
loss was present in five patients each. The average duration
of symptoms before revascularization was 22 months
(range, 2-36 months). In six patients (40%) with asymp-
tomatic high-grade mesenteric artery stenoses or occlu-
sions, revascularization was part of combined aortic recon-
structions for vasculitic involvement of the paravisceral
aorta and renal arteries (Table I).
Vasculitis was active in eight patients and in remission
in seven. The patients with active disease had arthralgias,
headaches, night sweats and fevers, or peripheral weakness.
Erythrocyte sedimentation rate was elevated in 8 patients
(mean, 30 mm/h; range 3-110 mm/h) and C reactive
protein in 1 (mean, 4 mg/L; range, 0.3-23 mg/L). Car-
diovascular risk factors included hypertension in 9, ciga-
rette smoking in 7, hyperlipidemia in 3, peripheral arterial
disease in 3, and diabetes in 1.
Distribution of vascular lesions. Fifteen patients had
29 diagnostic imaging studies, including computed tomog-
raphy (CT) in 11, biplane aortography with or without
selective mesenteric angiography in 9, magnetic resonance
imaging (MRI) in 6, and duplex ultrasound imaging in 3.
The lesions were long and tapered (Fig 1). A total of 70
vascular lesions were identified: 28 mesenteric and 42 ex-
tramesenteric. Mesenteric lesions affected the celiac axis in
13 patients, the superior mesenteric artery (SMA) in 13,
and the inferior mesenteric artery (IMA) in two. Of the 42
extramesenteric lesions, 19 involved the axillary-subclavian
arteries, 16 the renal arteries, 5 the aorta, and 2 the verte-
bral arteries (Fig 2, online only).
Pathology. One renal arterial wall, four mesenteric,
and seven aortic specimens from 10 patients were reviewed.
Eight were obtained from the anastomotic sites rather than
the diseased artery and showed no abnormalities. Ten
samples were full-thickness, and two contained only intima
and media. Four samples (3 aorta and 1 SMA) had chronic
lymphoplasmacytic granulomatous patterns with giant cells
(Fig 3, online only).
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medically, 10 at an average of 20 months preoperatively
(range, 2-120 months) and the other two after the proce-
dure. Eleven of the 12 received corticosteroids, 3 had
multiple immunosuppressive medications, including aza-
thioprine in 2, and cyclophosphamide in 1; and 1 patient
each received cyclosporine or methotrexate (Table I). The
three remaining patients had chronic disease and were not
treated with an immunosuppressant.
Mesenteric revascularization. Procedures included
open revascularization in 14 patients and percutaneous
Table I. A, Demographics, cardiovascular risk factors, and
revascularization for occlusive mesenteric vasculitis and ath
Pt
Age,
sex Type
Clinical
presentation Active Symptomatic Aorta
1 17, F TA HTN/HA Y N Suprarenal
stenosis
2 17, F TA HTN N N Midaortic
stenosis
3 15, F TA HTN N N Perirenal ao
2- to 3-c
stenosis
4 26, F TA HTN Y N Stenosis
5 44, F IN Chronic N Y
6 16, F TA Chronic/
HTN
N N Stenosis of
infrarena
aorta
7 27, F PAN Chronic N Y
8 51, F TA Chronic N Y
9 59, F IN Chronic Y Y
0 42, M PAN Chronic Y Y
1 41, F PAN HTN N Y
2 66, F GCA Chronic Y Y
3 51, F IN Chronic Y Y Aneurysma
4 58, M PAN Acute Y Y
5 33, F TA Chronic N Y
GCA,Giant cell arteritis;HA, headache;HTN, hypertension; IMA, inferior
polyarteritis nodosa; Severe, 75; SMA, superior mesenteric artery; TA, Tatransluminal angioplasty (PTA) of the SMA in one. Overall,22 mesenteric arteries were treated. The PTA was done as a
therapeutic trial because of atypical symptoms and to assess
symptom response because the patient had a short (2-cm)
focal stenosis of the SMA.The procedurewas performed from
the femoral approach with 6 mm 2 cm angioplasty balloon
using 0.035-inch system, with 40% residual stenosis. The
mesenteric symptoms improved, so open revascularization
was not needed.
Operations included reconstruction of the celiac and
SMA in 5 patients, SMA only in 5, aortoplasty with con-
comitant SMA patch angioplasty in 3, and median arcuate
nt of disease in patients treated with open
clerosis
Vessels involved
Celiac SMA Renal arteries IMA
Severe ostial
stenosis
Stenosis L renal stenosis
Ostial stenosis Ostial stenosis R renal stenosis
Ostial stenosis Minimal
stenosis
L renal stenosis
Ostial stenosis Ostial stenosis R renal 2-cm
stenosis, L 2
vessels
Ostial stenosis Ostial stenosis
Minimal ostial
stenosis
Moderate
stenosis
L renal 2 cm
moderate
stenosis; R
severe long
stenosis
Ostial stenosis
Severe ostial
stenosis
Occlusion Moderate stenosis
L renal, solitary
kidney
Severe
stenosis
Occlusion Occlusion
Ostial stenosis;
stenosis of
jejunal
branches
Lesion 1 cm
distal to the
origin
8-cm
narrowing at
the origin
Moderate stenosis
b/lateral
2 to 3-cm
ostial
stenosis
Short severe
stenosis
Severe ostial
stenosis
L severe ostial
stenosis
Severe
ostial
stenosis
Thickening
and long
stenosis,
splenic
artery
occlusion
Long stenosis
of the main
trunk
Minimal ostial
stenosis
Occlusion L 1-cm and R
moderate
stenosis
teric artery; IN, indeterminate;Minimal,50%;Moderate, 50%-75%; PAN,
’s arteritis.exte
eros
aortic
rta
m
l
l
mesenligament release with bovine pericardial patch angioplasty
xima
1
1
1
1
1
1
l PTA
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Volume 51, Number 2 Rits et al 395of the celiac axis in 1. Nine bypasses included four suprace-
liac single grafts, three supraceliac bifurcated grafts, and
two grafts originated from the common iliac artery (Fig 4).
The conduit was polyester in eight patients and reversed
saphenous vein in one. One patient underwent thoracoab-
dominal repair with four-vessel reimplantation. Combined
A
Fig 1. Imaging findings consistent with the diagnosis o
shows (A) significant arterial wall thickening (arrowhead
aortogram shows long smooth tapered lesions of the pro
Table I. B, Treatment and outcomes in patients treated w
and atherosclerosis
Pt Medical therapy Procedure date Surgical/en
1 Corticosteroids 5/1983 Aortoplasty celiac, SM
bypass
2 None 8/1983 Ao-SMA/R Renal
3 None 10/1985 Endarterectomy of A
aortoplasty, pantalo
renal arteries
4 Corticosteroids
(on DC)
3/1987 Aortoplasty with Dac
endarterectomy of
5 Corticosteroids 6/1991 Ao-CA-SMA
6 Corticosteroids 12/1995 R renal from Ao bypa
bypass, SMA from
7 Corticosteroids, AZA 1/1998 Arcuate ligament rele
8 Corticosteroids 6/1999 Ao-CA-SMA
9 Corticosteroids
(on DC)
5/2000 Ao-CA-SMA
0 Corticosteroids 6/2002 Ao-SMA
1 None 10/2004 SMA PTA
2 Corticosteroids 5/2005 Ao-SMA/Renals
3 Corticosteroids,
cyclosporine,
methotrexate, AZA
7/2006 Thoracoabdominal re
reimplantation
4 Corticosteroids 7/2007 IL-SMA
5 Corticosteroids 4/2008 Ao-SMA/Renals
AA, Abdominal aorta; Ao-CA-SMA, aortoceliac-SMA bypass; Ao-SMA,
azathioprine; DC, discharge; IL-SMA, ileo-SMA bypass; GI, gastrointestina
superior mesenteric vein.aortic reconstruction was required in four patients (3 aor-toplasties and 1 graft) for three symptomatic stenoses and
one paravisceral aneurysm. Seven patients needed 12 renal
artery reconstructions (10 bypasses and 2 patch angioplas-
ties) because of medically refractory renovascular hyperten-
sion caused by renal artery vasculitis. All patients underwent
intraoperative ultrasound imaging at the end of the proce-
B C
senteric vasculitis. Computed tomography angiography
(B) a long, smooth tapered lesion (arrow). C, A lateral
l celiac axis and superior mesenteric artery (arrows).
pen revascularization for occlusive mesenteric vasculitis
cular therapy Early outcome Late outcome
lation with L renal No comp 22 mon, patent
No comp 8 mon, patent
ation of celiac,
ein graft to b/lateral
No comp 19 mon, patent
MA endarterectomy,
arteries
Ileus with
re-exploration
16 mon, patent
No comp 120 mon, patent
renal from aortic graft
bypass
No comp 90 mon, patent
No comp 122 mon, patent
No comp 7 mon, patent
SMV thrombosis Celiac limb occlusion
at 74 mon with
revision
No comp 68 mon, patent
No comp 30 mon, patent
No comp 11 mon, patent
ith vessel No comp 10 mon, patent
GI bleed 8 mon, patent
No comp 8 mon, patent
SMA bypass; Ao-SMA/Renals, aorto-SMA and b/l renals bypass; AZA,
, percutaneous balloon angioplasty; SMA, superior mesenteric artery; SMV,f me
s) andith o
dovas
A di
A, dil
on v
ron, S
renal
ss, L
CIA
ase
pair w
aorto-dure or at dismissal.
lar h
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renal, cardiac, or pulmonary complications were docu-
mented. The average hospital length of stay was 13 days
(range, 1-45 days). Gastrointestinal bleeding, ileus requir-
ing re-exploration, and superior mesenteric vein (SMV)
thrombosis occurred in one patient each. The patient with
SMV thrombosis did not have thrombophilia but was
treated with anticoagulation. In the subset of patients who
had concomitant renal reconstructions, mean preoperative
and postoperative creatinine levels were 0.9  0.4 and
0.8  0.4 mg/dL, respectively. The nine symptomatic
patients improved immediately after treatment, and patent
mesenteric arteries at dismissal were verified in all patients
A
B
Fig 4. A, Open mesenteric revascularization for mesen
artery bypass or (B) a supraceliac aorta to superior m
concomitant bilateral renal artery stenoses and renovascuby ultrasound imaging or CT.Late outcomes. There were no late deaths after a
mean follow-up of 41 months (median, 22 months; range,
7-120 months). All patients reported symptom improve-
ment at their last follow-up. In the seven patients who had
renal revascularization, the average of three outpatient
blood pressure measurements decreased from 162 
42/87  10 mm Hg preoperatively to 119  19/67  7
mm Hg postoperatively (P  .01).
Fourteen patients (93%) remained asymptomatic.
Thrombosis of the celiac limb and high-grade stenosis of
the SMA limb at 74 months caused subacute symptoms in
the other patient with an aorta-celiac and SMA bypass. This
was treated with patch angioplasty of the SMA graft, which
vasculitis was with an iliac artery to superior mesenteric
eric and bilateral renal artery bypass in a patient with
ypertension.teric
esentwas patent 9 months later. There were no additional reste-
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plex ultrasound imaging at 40 months showed a patent
artery in the patient treated with SMA angioplasty.
Comparisons with atherosclerotic disease. The clin-
ical data and late results of the 14 patients with mesenteric
vasculitis who underwent operations were compared with the
outcomes of 163 patients with 287 arteries reconstructed for
chronic atherosclerotic mesenteric ischemia. These recon-
structions included the celiac and SMA in 109 patients (76%)
and a single SMA reconstruction in 53 (24%).
Patients with vasculitis were 3 decades younger (mean,
38 vs 65 years old; P  .01) and had significantly fewer
cardiovascular risk factors (P  .05), including less hyper-
tension (53% vs 77%), hyperlipidemia (20% vs 51%), and
tobacco use (37% vs 76%).
Primary graft patency at 5- and 10-years was 83% in the
vasculitis group and 92% and 84% in the atherosclerotic
group (P  .68; Fig 5). Freedom from mesenteric symp-
toms at 10 years was 83% for patients with vasculitis and
75% for those with atherosclerotic disease (P .68; Fig 6).
Cumulative survival estimate at 10 years was 100% in
the vasculitis group (SE 0, Fig 7, online only), similar to
the 98% expected survival of age- and gender-matched
controls from the State of Minnesota (P  .69). However,
10-year survival in patients with atherosclerosis was mark-
edly decreased at 45% (P  .0001, Fig 7, online only).
DISCUSSION
The incidence of vasculitis is low, affecting 20 individ-
uals per million each year.1 Involvement of the mesenteric
arteries is noted in up to 50% of patients diagnosed with
vasculitis, but only 16% have isolated mesenteric arterial
involvement.5 The disorders most commonly implicated are
Takayasu arteritis due to aortic involvement proximal to or at
the ostia of the mesenteric arteries, giant cell arteritis, and
Fig 5. Primary graft patency is shown in patients treated with
open revascularization for mesenteric vasculitis (MV) and for ath-
erosclerotic (ASO) disease.polyarteritis nodosa, which typically presents with multipleaneurysms. However, Wegener granulomatosis, Churg-
Strauss syndrome, microscopic polyangiitis, and other
small-vessel arteriopathies also may affect the mesenteric
circulation.6 Most patients are asymptomatic, and mesen-
teric involvement is discovered because of systemic, cere-
brovascular, or renal manifestations of the disease, as oc-
curred in one-third of our patients. Symptoms of acute or
chronic mesenteric ischemia are rare. Most symptomatic
patients present with bleeding from gastrointestinal muco-
sal erosions or from small aneurysms of the distal mesen-
teric or hepatic artery branches.2
Because vasculitis is primarily an inflammatory process,
corticosteroids alone or combined with other immunosup-
pressants are the basis of medical therapy. Our medical
regimen is based on previous work published from our
institution,7,8 which includes a daily dose of 40 to 60 mg of
prednisone, which we prefer over a lower dose or alternate
day corticosteroid therapy, and aspirin.8 Prednisone is
maintained at this dosage for approximately 4 to 6 weeks,
after which it is tapered by 10% every 2 to 4 weeks,
depending on absence of symptoms and levels of inflamma-
tory markers. The addition of an antimetabolitic or steroid-
sparing agent may allow reduction of the prednisone dose,
although these medications are reserved for patients with-
out an initial response to prednisone.7,8 Although medical
treatment effectively resolved mesenteric symptoms in
87% of our patients, the indications, timing, approach
and outcomes of mesenteric revascularization, when
needed, have been poorly described. We reserve operation
for failure of medical therapy in the acute or chronic setting,
or because of severe side effects from the immunosuppres-
sive medications.
Similar to our experience with the management of
occlusive lesions from Takayasu arteritis, we prefer open
arterial reconstruction in most patients with vasculitis, in-
Fig 6. Freedom from mesenteric symptoms in the patients
treated for mesenteric vasculitis (MV) vs atherosclerosis (ASO).dependent of vascular territory.9 We have learned that the
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when the arteritis is quiescent, and preferably when they are
no longer taking steroids.
Our operative approach to patients with mesenteric vas-
culitis has evolved over the years. Before 1990, we prophylac-
tically reconstructed a mesenteric artery if it was severely
stenotic, even when the primary indication for operation was
abdominal aortic coarctation, aneurysm, or renovascular hy-
pertension. This was most often done because reoperation to
revascularize a visceral artery would have been difficult, a view
shared by Stanley et al.10 Currently, mesenteric revasculariza-
tion is done for symptomatic patients and selectively for those
who effectively have three-vessel involvements, either with
mesenteric trunk disease or aortic coarctation involving the
origins of all three arteries.
There are no guidelines for how to approach open
mesenteric reconstruction in patients with vasculitis. The
general principal is for the inflow and outflow anastomoses
to be done to noninflamed arteries. Similar to the patients
with atherosclerotic mesenteric disease, we favor an ante-
Table II. Summary of clinical reports dealing with open a
First author (Year)
Vasculitis
Type No.
Mean
age
Gender
(M/F)
Tyagi (1993)23 TA 1 21 0/1
Kempczinski
(1993)14
TA 1 38 0/1
Hodgins (1984)15 TA, 2 2 34 0/1
34 0/1
Tyagi (1997)13 TA 1 21 0/1
Zhul (2006)16 TA 1 36 1/0
Ozdil (1996)17 TA 1 49 0/1
Arguedas (2000)18 GCA 1 72 0/1
Chubachi (1993)19 Behçet 1 37 1/0
Sujobert (2007)20 GCA, 4 4 73
Scola (2008)21 GCA, 2 2 72 0/2
Lacombe (2002)22 TA, 3 3 20 1/2
Fields (2006)9 TA, 5 5 29 1/4
Min (2005)24a TA (25) 2 37 3/22
Esato (1982)25 TA 1 36 0/1
TA
Scott (1986)26b TA (6) 2 17 5/1
Kalangos (2006)27c (10) 4 13 5/5
Ao-CA, Aortoceliac bypass; Il-SMA, ilio-SMA bypass; Ao-CA-SMA, aortoc
arteritis;M/F,male and female ratio; PTA, percutaneous transluminal angio
mesenteric artery; TA, Takayasu arteritis.
aTotal of 25 patients treated, 2 with mesenteric lesions.
bTotal of 6 patients 2 with mesenteric lesions.
cTotal of 10 patients with 4 mesenteric lesions.grade bypass from the supraceliac aorta, whenever possible.Both the celiac and SMA are reconstructed with a bifur-
cated graft, because we believe that late failure of one graft
doesn’t necessarily result in recurrent symptoms.11,12 If the
patient is older and has cardiac disease or a calcified non-
stenotic aorta, we prefer a retrograde iliomesenteric bypass
with a straight or C-shaped configuration, as was needed in
two of our patients.11,12 Finally, although concomitant
aortic and renal reconstructions are avoided in most pa-
tients treated for atherosclerotic chronic mesenteric isch-
emia because of the high mortality and morbidity, these
vasculitic patients may need them. Seven of the 15 patients
(47%) with mesenteric vasculitis also had refractory hyper-
tension and required bypass of the renal arteries, and four
(27%) had asymptomatic but preocclusive mesenteric le-
sions, which were bypassed in conjunction with aortic and
renal reconstructions.
Aortic reconstruction may be required for aneurysm
(rare) or suprarenal coarctation. Although we use aorto-
plasty for patients with developmental coarctation when
the lumen permits, as Stanley espouses, aortoaortic bypass
ndovascular revascularization for mesenteric vasculitis
Type of revascularization
OutcomeOpen Endo
SMA PTA 6 mon, pain-free
CA-SMA 6 mon, symptom-free
SMA PTA Recurrent abdominal pain
in 3 mon, redilation,
symptom-free 6 mon
SMA Occlusion of bypass in 3
yrs
SMA PTA 6 mon, symptom-free
SMA 6 mon, symptom-free
SMA-CA
PTAS
8 mon, symptom-free
MA DC from the hospital,
symptomatic relief
SMA 3 mon, improvement in
symptoms
and bypass No follow-up
MA SMA PTA Clinical improvement
SMA, 3 1 acute revision
SMA and Ao-CA Clinical improvement
PTAS 26% restenosis at mean
17-mon follow-up
omboendarterectomy 4 mon symptom-free
2 and 6 yrs symptom-free
lenic, Il-SMA Occlusion of SMA
bypasses at 12 and 17
yrs
R, SMA, HA; Il-
MA, Renal; Ao-renal,
MA
PTA
MA bypass; Ao-SMA, aorto-SMA bypass; DC, discharge; GCA, giant cell
; PTAS, percutaneous transluminal angioplasty and stenting; SMA, superiornd e
Ao-
Ao-
Ao-
Il-S
Ao-
PTA
Il-S
Ao-
Ao-
Thr
Il-sp
Ao-
S
S
eliac-S
plastyis required as an inflow source for those with periaortic
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often have symptomatic renal artery stenosis.
A literature search using the Medline database from
1965 to 2008 found 16 reports of open or endovascular
revascularizations for mesenteric vasculitis in 32 pa-
tients.9,13-27 Table II summarizes the demographics, diag-
noses, and outcomes these patients, who were treated with
20 open surgical and 12 endovascular procedures. Most
patients were young women. Similar to our findings, the
three most common diagnoses were Takayasu arteritis,
giant cell arteritis, and polyarteritis nodosa. Most patients
had mesenteric ischemia, which improved after reconstruc-
tion. Follow-up was1 year in all but one report or was not
reported beyond the hospital dismissal. No patients died,
although two of the 20 patients treated with open revascu-
larization required reoperation for early graft thrombosis or
late restenosis. Among the 12 patients treated with PTA,
one patient with recurrent mesenteric ischemia at 3 months
was retreated with another angioplasty. However, no con-
clusions can be reached about the role of endovascular
therapy because of the short follow-up in the 12 patients.
Only one of our patients was treated with angioplasty of
an isolated, focal SMA lesion because of atypical symptoms,
and that treatment was durable. Theoretically, preferential
use of endovascular intervention in such patients faces some
challenges:
First, the durability of mesenteric angioplasty in pa-
tients with atherosclerotic disease has not matched the
results obtained with open surgical bypasses.28 This be-
comes a major limitation for these younger patients with
normal life expectancy.
Second, long, tubular vasculitic lesions are prone to
recoil, which may lead to a poor technical result or early
failure without long stents.
Third, angioplasty or stent placement contradicts the
basic principle of avoiding the inflammatory bed, especially
in patients with active disease, acute inflammation, or those
with chronic disease still on steroids. This patient subset in
Takayasu arteritis causes the highest level of restenosis and
occlusion.9
Several study limitations deserve comment. Because
the disease is rare, our study spanned2 decades to collect
15 patients treated for a variety of vasculitides with different
types of procedures. Substantial advances in diagnostic
imaging, medical therapy, and revascularization techniques
occurred during this time. The exact circumstances in-
volved in the clinical decision making, such as choice of the
medications and the timing, method, and the extent of
reconstruction, are difficult to determine because of the
retrospective design. Finally, follow-up imaging of mesen-
teric grafts was not uniformly available, which may under-
estimate restenoses rates.
CONCLUSIONS
Occlusive mesenteric vasculitis is a rare manifestation of
Takayasu arteritis, polyarteritis nodosa, giant cell, or other
vasculitides. Involvement of other vascular territories is
common. The choice of reconstruction depends on theassociated aortic inflammation, but open surgical recon-
structions are durable and effective when needed.
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and David Factor for the medical illustrations.
AUTHOR CONTRIBUTIONS
Conception and design: GO
Analysis and interpretation: YR, GO, TB, LC, DM, JR,
MK, PG
Data collection: YR
Writing the article: YR, GO, TB, LC, DM, JR, MK, PG
Critical revision of the article: YR, GO, TB, LC, DM, JR,
MK, PG
Final approval of the article: YR, GO, TB, LC, DM, JR,
MK, PG
Statistical analysis: YR, GO, TB
Obtained funding: GO
Overall responsibility: GO
REFERENCES
1. Morgan MD, Savage CO. Vasculitis in the gastrointestinal tract. Best
Pract Res Clin Gastroenterol 2005;19:215-33.
2. Langford CA. 15. Vasculitis. J Allergy Clin Immunol 2003;111(2
suppl):S602-12.
3. Yazici Y. Vasculitis update, 2007. Bull NYU Hosp Jt Dis 2007;65:
212-4.
4. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al.
Nomenclature of systemic vasculitides. Proposal of an international
consensus conference. Arthritis Rheum 1994;37:187-92.
5. Casella G, Bronzino B, Cutrino L, Montani N, Somma A, Baldini V.
Vasculitis and gastrointestinal involvement. Minerva Gastroenterol Di-
etol 2006;52:195-214.
6. Guillevin L, Dorner T. Vasculitis: mechanisms involved and clinical
manifestations. Arthritis Res Ther 2007;9(suppl 2):S9.
7. Warrington KJ, Matteson EL. Management guidelines and outcome
measures in giant cell arteritis (GCA). Clin Exp Rheumatol 2007;25:
137-41.
8. Hunder GG, Sheps SG, Allen GL, Joyce JW. Daily and alternate-day
corticosteroid regimens in treatment of giant cell arteritis: comparison
in a prospective study. Ann Intern Med 1975;82:613-8.
9. Fields CE, Bower TC, Cooper LT, Hoskin T, Noel AA, Panneton JM,
et al. Takayasu’s arteritis: operative results and influence of disease
activity. J Vasc Surg 2006;43:64-71.
10. Stanley JC, Criado E, Eliason JL, Upchurch GR Jr, Berguer R, Rect-
enwald JE. Abdominal aortic coarctation: surgical treatment of 53
patients with a thoracoabdominal bypass, patch aortoplasty, or interpo-
sition aortoaortic graft. J Vasc Surg 2008;48:1073-82.
11. Park WM, Gloviczki P, Cherry KJ Jr, Hallett JW Jr, Bower TC,
Panneton JM, et al. Contemporary management of acute mesenteric
ischemia: factors associated with survival. J Vasc Surg 2002;35:
445-52.
12. Foley MI, Moneta GL, Abou-Zamzam AM Jr, Edwards JM, Taylor
LM Jr, Yeager RA, et al. Revascularization of the superior mesenteric
artery alone for treatment of intestinal ischemia. J Vasc Surg 2000;
32:37-47.
13. Tyagi S, Verma PK, Kumar N, Arora R. Stent angioplasty for relief of
chronic mesenteric ischemia in Takayasu arteritis. Indian Heart J 1997;
49:315-8.
14. Kempczinski RF, Clark SM, Blebea J, Koelliker DD, Fenoglio-Preiser
C. Intestinal ischemia secondary to thromboangiitis obliterans. Ann
Vasc Surg 1993;7:354-8.
15. Hodgins GW, Dutton JW. Transluminal dilatation for Takayasu’s ar-
teritis. Can J Surg 1984;27:355-7.
JOURNAL OF VASCULAR SURGERY
February 2010400 Rits et al16. Zhu T, Fu WG, Chen B, Shi ZY, Guo DQ, Jiang JH, et al. Visceral and
renal arteries stenosis associated with Takayasu arteritis. Chin Med J
(Engl) 2006;119:786-8.
17. Ozdil E, Parikh DK, Krajcer Z, Angelini P. Stent placement in a patient
with Takayasu’s arteritis. Cathet Cardiovasc Diagn 1996;38:373-6.
18. Arguedas MR, Linder JD. Giant cell arteritis and intestinal angina. Dig
Dis Sci 2000;45:2363-4.
19. Chubachi A, Saitoh K, Imai H, Miura AB, Kotanagi H, Abe T, et al.
Case report: intestinal infarction after an aneurysmal occlusion of supe-
rior mesenteric artery in a patient with Behcet’s disease. Am J Med Sci
1993;306:376-8.
20. Sujobert P, Fardet L, Marie I, Duhaut P, Cohen P, Grange C, et al.
Mesenteric ischemia in giant cell arteritis: 6 cases and a systematic
review. J Rheumatol 2007;34:1727-32.
21. Scola CJ, Li C, Upchurch KS. Mesenteric involvement in giant cell
arteritis. An underrecognized complication? Analysis of a case series
with clinicoanatomic correlation. Medicine 2008;87:45-51.
22. LacombeM. [Renal and aortic localizations in Takayasu’s disease]. Ann
Chir 2002;127:268-75.
23. Tyagi S, Jolly N, Khalilullah M. Multivessel angioplasty in Takayasu’s
arteritis. Indian Heart J 1993;45:215-7.
24. Min PK, Park S, Jung JH, Ko YG, Choi D, Jang Y, et al. Endovasculararterial disease in patients with Takayasu’s arteritis. J Endovasc Ther
2005;12:28-34.
25. Esato K, Noma F, Kurata S, Oda E, Mohri H. Mesenteric infarction in
Takayasu’s arteritis treated by thromboendarterectomy and intestinal
resection. Jpn J Surg 1982;12:130-4.
26. Scott D, Awang H, Sulieman B, Wang F, Arshad RB, Thomson N.
Surgical repair of visceral artery occlusions in Takayasu’s disease. J Vasc
Surg 1986;3:904-10.
27. Kalangos A, Christenson JT, Cikirikcioglu M, Vala D, Buerge A,
Simonet F, et al. Long-term outcome after surgical intervention and
interventional procedures for the management of Takayasu’s arteritis in
children. J Thorac Cardiovasc Surg 2006;132:656-64.
28. Atkins MD, Kwolek CJ, LaMuraglia GM, Brewster DC, Chung TK,
Cambria RP. Surgical revascularization versus endovascular therapy for
chronic mesenteric ischemia: a comparative experience. J Vasc Surg
2007;45:1162-71.
Submitted Feb 22, 2009; accepted Aug 26, 2009.
Additional material for this article may be found online
therapy combined with immunosuppressive treatment for occlusive at www.jvascsurg.org.
AVAILABILITY OF JOURNAL BACK ISSUES
As a service to our subscribers, copies of back issues of Journal of Vascular Surgery for the preceding 5 years are
maintained and are available for purchase from Mosby until inventory is depleted. Please write to Elsevier Inc.,
Subscription Customer Service, 11830 Westline Industrial Drive, St. Louis, MO, or call 800-654-2452 (U.S. and
Canada); 314-453-7041 (outside U.S. and Canada) for information on availability of particular issues and prices.
inferior mesenteric artery (IMA).
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Volume 51, Number 2 Rits et al 400.e1Fig 2. (online only). Distribution of mesenteric and extrames-
enteric lesions in patient with occlusive mesenteric vasculitis in-
volving the celiac axis, superior mesenteric artery (SMA) and
JOURNAL OF VASCULAR SURGERY
February 2010400.e2 Rits et alFig 3. (online only). Histologic examination arterial wall biopsy obtained from the patient described in Fig 1
confirmed the diagnosis of giant cell arteritis, showing chronic lymphoplasmacytic vasculitis with patchy transmural
inflammation and periadventitial fibrosis. A, Hematoxylin and eosin (H&E) stain at original magnification 12.5.
B, The arrow designates a multinucleated giant cell (H&E; original magnification 200).Fig 7. (online only). Kaplan-Meyer survival curves of the pa-
tients treated for mesenteric vasculitis (MV) compared with Min-
nesota (MN) age- and gender-matched controls vs patients treated
for atherosclerosis (ASO).
